Today Nanomerics is pleased to announce that the publication (SARS-CoV-2 inhibition using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray | Scientific Reports (nature.com)announcing the viral inhibition activity of AnQlar™️, and published inScientific Reports, has been downloaded over 3600 times since its publication in October 2021 and cited 14 times. The publication details the activity of AnQlar™️ against the SARS-COV-2 virus. Infections with the SARS-COV-2 virus result in a respiratory illness - COVID-19, which can be fatal. In 2020, COVID19 infections spread around the world, resulting in a global shutdown. The shutdown was aimed at reducing the death toll arising from the pandemic. Many vaccines have been developed in the past two years, but it is widely agreed that these vaccines do not stop transmission of the virus. AnQlar™️ has been formulated into a nasal spray to reduce transmission of the virus and thus will be indicated for use as a prophylaxis against COVID19. AnQlar™️ has been out-licensed to Virpax Pharmaceuticals (NASDAQ:VRPX). Virpax Pharmaceuticals is developing AnQlar™️ nasal spray as an over-the-counter prophylactic against a range of respiratory viral infections.
Anti-COVID19 prophylactic paper published in October 2021 already downloaded over 3600 times
Updated: Jan 5